Anzeige
Mehr »
Login
Sonntag, 10.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Breaking News: Das geheime Potenzial von 55?$ pro Aktie in einem Clean-Energy-Deal!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PJ5B | ISIN: KYG4672N1198 | Ticker-Symbol: H7T2
Frankfurt
08.11.24
08:05 Uhr
3,260 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
HUTCHMED CHINA LIMITED Chart 1 Jahr
5-Tage-Chart
HUTCHMED CHINA LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
3,1403,54009.11.
3,4203,58005.11.

Aktuelle News zur HUTCHMED Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiHUTCHMED Ltd - 6-K, Report of foreign issuer-
MiHutchmed China Ltd - Clinical Data to be Presented at ASH and ESMO Asia-
MiHUTCHMED (China) Limited: HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress1
MiHUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED HIGHLIGHTS CLINICAL DATA TO BE PRESENTED AT THE 2024 ASH ANNUAL MEETING AND THE 2024 ESMO ASIA CONGRESS1
31.10.Hutchmed China receives first milestone payment for Takeda drug sales6
31.10.Hutchmed to receive $20m Fruzaqla milestone payment2
31.10.HUTCHMED (China) Limited: HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA (fruquintinib) Sales by Takeda94HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:?HCM; HKEX:?13) today announces that it will receive a US$20 million...
► Artikel lesen
31.10.HUTCHMED (00013): TOTAL VOTING RIGHTS1
31.10.HUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED TO RECEIVE FIRST COMMERCIAL MILESTONE PAYMENT FOLLOWING OVER US$200 MILLION IN FRUZAQLA (FRUQUINTINIB) ...3
31.10.Hutchmed China Ltd - Total Voting Rights-
31.10.Hutchmed China Ltd - First Commercial Milestone Payment-
21.10.HUTCHMED (00013): VESTING OF AWARDS UNDER THE LONG TERM INCENTIVE PLAN-
21.10.Hutchmed China Ltd - Vesting of awards under the LTIP-
16.10.Hutchmed reports positive results from AstraZeneca lung cancer collaboration4
16.10.HUTCHMED Ltd - 6-K, Report of foreign issuer1
16.10.Hutchmed China Ltd - SAVANNAH: clinically meaningful response rate-
16.10.HUTCHMED (China) Limited: HUTCHMED Announces that TAGRISSO plus ORPATHYS demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase ...61- New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer - - MET is a common biomarker in this setting for patients who develop...
► Artikel lesen
16.10.HUTCHMED (00013): HUTCHMED ANNOUNCES THAT TAGRISSO PLUS ORPATHYS DEMONSTRATED HIGH, CLINICALLY MEANINGFUL RESPONSE RATE IN LUNG CANCER PATIENTS WITH HIGH ...2
11.10.HUTCHMED (NASDAQ:HCM) Stock Price Down 2.3% - Should You Sell?1
10.10.AIM WINNERS & LOSERS: Windward rises; Hutchmed recovers1
Seite:  Weiter >>
138 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1